Biohaven Ltd.

Healthcare · Biotechnology · United States

Last price 15.42 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.33B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim...